Immunovia Ab · OMXSTO:IMMNOV
Immunovia Ab — Penser Conference (November 2022)
16 slides from Immunovia Ab's conference presentation, November 2022
Slide 1: Investor Presentation
Investor Presentation November 2022
Slide 2: Forward looking statements
Forward looking statements • IMPORTANT: The following applies to this document, the oral presentation of the information in this document by Immunovia AB (publ) (the “Company”) or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectivel
Slide 3: Revolutionizing blood-based diagnostics to advance early detection of pancreatic cancer
Revolutionizing blood-based diagnostics to advance early detection of pancreatic cancer and increase patient survival rates 2021-09-24 3
Slide 4: Establishing the leader in the early detection of pancreatic cancer
Establishing the leader in the early detection of pancreatic cancer Front-runner in non-invasive early detection Initial US patient population of over 1.8 million in of pancreatic cancer (PDAC) pancreatic cancer Revolutionizing blood-based Incorporated 2007 in Sweden, 2017 in US diagnostics to Comme
Slide 5: Pancreatic is one of the most lethal cancers with limited diagnostic innovation
Pancreatic is one of the most lethal cancers with limited diagnostic innovation US deaths by cancer 2020 5-year survival rates: Lung 138,225 22.8% Colorectum 54,443 65.1% Pancreas 47,638 11.5% Breast 42,617 90.6% Prostate 32,428 96.8% Liver 31,078 20.8% Non-Hodgkin lymphona 20,858 73.8% Brain, centr
Slide 6: Patients are often diagnosed too late when surgery is no longer an option
Patients are often diagnosed too late when surgery is no longer an option 42% <20% Early Dx 80% Late Dx 3% 5-year survival rate 5-year survival rate when diagnosed early when found late (surgical optionality) (metastatic, non-resectable) Treatment methods: Treatment methods: • Chemotherapy • Chemoth
Slide 7: US addressable patient population of over 1.8 million patients
US addressable patient population of over 1.8 million patients 2022 Total Addressable Patient Population Surveillance Markets ~1M patients • Surveillance generally involves annual imaging to detect pancreatic cancer in high-risk individuals: • Individuals with a family history of pancreatic cancer o
Slide 8: Limitations in current standard of care for pancreatic cancer diagnosis
Limitations in current standard of care for pancreatic cancer diagnosis Imaging frequently fails Too few patients under Imaging is burdensome Imaging results can be to identify pancreatic surveillance for patients inconclusive cancer early • Only 21% of patients who • Both MRCP and • Small tumors ar
Slide 9: Revolutionary blood-based test: IMMray PanCan-d
Revolutionary blood-based test: IMMray® PanCan-d First US blood-based First-to-market advantage pancreatic cancer monitoring test Accurate microarray Unique “disease fingerprints” patented technology from a blood sample Significant unmet US addressable market size of medical need over 1.8 million pa
Slide 10: IMMray PanCan-d provides specific, actionable results
IMMray® PanCan-d provides specific, actionable results Immunovia Medical HIGH-RISK SIGNATURE Director calls ordering Serum is classified as high-risk for pancreatic cancer PRESENT physician; prompt clinical evaluation NEGATIVE FOR Continue with regular Serum is classified as low-risk for pancreatic
Slide 11: Broad clinical validation of IMMray PanCan-d
Broad clinical validation of IMMray® PanCan-d Blinded validation study Commercial test model study Verification study (Publication: Clin Transl Gastroenterol. 2022) 2020 2020 2022 PDAC stage I-II versus healthy PDAC stage I-II versus healthy PDAC stage I-II versus familial/hereditary 1,113 patient s
Slide 12: Extensive key opinion leader & advocacy network
Extensive key opinion leader & advocacy network Advocacy Partner Organizations Key Research and Clinical Collaborators Commercial strategy leverages KOL relationships and patient advocacy collaborations 12
Slide 13: Staged approach to commercializing IMMray PanCan-d
Staged approach to commercializing IMMray PanCan-d PHASE LAUNCH (CURRENT) GROWTH (MEDIUM-TERM) EXPANSION (LONG-TERM) Genetic and familial risk factors Genetic and familial risk factors Genetic and familial risk factors Intended Uses in IPMNs (cysts) IPMNs (cysts) Pancreatic Cancer Detection Chronic
Slide 14: Executing reimbursement plan for US insurance coverage
Executing reimbursement plan for US insurance coverage Extensive payer insights obtained (2021) CAP accreditation received (2021) Peer reviewed blinded validation study published (2021) Physician experience program initiated (2022) PLA code approved (2022) Head of Market Access hired (2022) Pricing
Slide 15: Establishing the leader in the early detection of pancreatic cancer
Establishing the leader in the early detection of pancreatic cancer AREA 2022 ACCOMPLISHMENTS OPERATIONAL ✓ Clear strategic focus on pancreatic cancer ✓ Secured CAP accreditation ✓ Hired experienced commercial leader as US CEO ✓ Expanded sales team ✓ Entered into R&D alliance with Proteomedix ADOPTI
Slide 16: Q&A
16 Q&A helloir@immunovia.com www.immunovia.com 2021-09-24 16